EILEAN THERAPEUTICS INITIATES FIRST IN HUMAN TRIAL WITH EILETOCLAX, A SELECTIVE BCL2 INHIBITOR WITH LIMITED IMMUNE SUPPRESSION AND IMPROVED SAFETY COMPARED TO VENETOCLAX AND VENETOCLAX-LIKE MOLECULES

On January 29, 2024 Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, reported the clearance from the Human Research Ethics Committee in Australia to begin human dosing in the Phase 1 clinical program of eiletoclax, a highly potent and selective BCL2 inhibitor (Press release, Eilean Therapeutics, JAN 29, 2024, View Source [SID1234639696]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The first in human dosing of eiletoclax in Australia represents another important milestone for Eilean Therapeutics, as we progress, with an accelerated development of our portfolio of best-in-class agents targeting hematological malignancies," stated Iain Dukes, Chief Executive Officer of Eilean Therapeutics. "The highly differentiated pre-clinical profile of eiletoclax emphasizes important advantages over venetoclax-like molecules in safety, tolerability and feasibility of outpatient treatment, enabling the molecule to safely target AML and CLL patients alone and in combination with other targeted therapies."

About Eiletoclax

Eiletoclax (ZE50-0134) has earlier reported best-in-class potency and selectivity against BCL2, a key pro-survival protein that is overexpressed in many cancers. This clinical candidate demonstrated equivalent in vivo anti-tumor efficacy as venetoclax in B cell and myeloid malignancy cell lines and in vivo models. Compared to venetoclax, eiletoclax exhibits significantly less suppression of non-malignant immune cell populations, a result that suggests superior selectivity and an improved safety profile.